Statistics on Biotechnology Use  
Results by fields of operation
Total Sectors. Biotechnology indicators by execution sector. 
Unidades: 

;Total 2021;Companies;P.A.;Higher Education;PNPI;
Companies that perform R+D in Biotechnology;1.547;1.348;120;66;13;
%Companies according to biotechnology used: Genetic code;38;31;87,5;89,4;46,2;
%Companies according to biotechnology used: Functional Companies;44,8;38,4;88,3;93,9;53,8;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;28,8;21,7;73,3;86,4;61,5;
%Companies according to biotechnology used: Bioprocesses;53;50,3;58,3;93,9;69,2;
%Companies according to biotechnology used: Sub-cellular organisms;14,8;8,2;53,3;74,2;38,5;
%Companies according to biotechnology used: Bio-computing;30,7;24,1;73,3;87,9;30,8;
%Companies according to biotechnology used: Nanobiotechnology;17,7;11,8;54,2;72,7;15,4;
%Companies according to biotechnology used: Other;14,9;16,4;3,3;7,6;0;
Companies in which biotechnology activities are:  Main and/or exclusive;705;661;31;3;10;
Companies in which biotechnology activities are: A secondary line of business;276;188;41;46;1;
Companies in which biotechnology activities are: A tool necessary for production;567;500;48;17;2;
%Companies by field(s) of ultimate application of biotechnology use: Human Health;50,5;45,8;76,7;95,5;69,2;
%Companies by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;17,8;15,3;17,5;69,7;23,1;
%Companies by field(s) of ultimate application of biotechnology use: Food products;32,9;31,5;24,2;81,8;7,7;
%Companies by field(s) of ultimate application of biotechnology use: Agriculture and forest production;25,7;23,7;22,5;72,7;23,1;
%Companies by field(s) of ultimate application of biotechnology use: Environment;19;15,5;25,8;78,8;7,7;
%Companies by field(s) of ultimate application of biotechnology use: Industry;15,8;13,4;14,2;68,2;7,7;
Personnel in R&D in biotechnology (no. of persons);47.144;15.744;15.418;15.757;225;
Personnel in R&D in biotechnology (no. of persons): Research personnel;30.818;8.380;9.510;12.778;150;
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;16.326;7.364;5.908;2.979;75;
Personnel in R&D in biotechnology (no. of persons). Women;26.646;8.725;9.684;8.101;136;
Personnel in R&D in biotechnology (no. of persons). Women. Research personnel;16.551;4.521;5.637;6.314;79;
Personnel in R&D in biotechnology (no. of persons). Women. Technical and auxiliary personnel;10.095;4.204;4.047;1.787;57;
Personnel in R&D in biotechnology (FTE);32.896,3;11.523,2;11.271,7;9.934,5;166,9;
Personnel in R&D in biotechnology (FTE): Research personnel;20.944,7;6.341,6;6.454,3;8.036;112,8;
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;11.951,6;5.181,6;4.817,4;1.898,5;54,1;
Personnel in R&D in biotechnology (FTE). Women;18.965,5;6.552,7;7.077,3;5.228;107,5;
Personnel in R&D in biotechnology (FTE). Women: Research personnel;11.346;3.464,4;3.786,8;4.032,9;61,9;
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;7.619,5;3.088,3;3.290,5;1.195,1;45,6;
Internal expenditure on R&D (thousands of euros);2.269.251;1.037.887;716.877;500.703;13.783;
1) By nature of the expense: Current expenses;2.086.468;939.471;672.607;461.216;13.174;
1.1) Remuneration to research personnel;872.151;321.525;252.863;293.131;4.630;
1.2) Remuneration to technicians and auxiliary personnel;384.242;194.656;128.640;59.408;1.538;
1.3) Other current expenses;830.076;423.290;291.103;108.677;7.006;
2) By nature of the expense: Capital expenses;182.782;98.416;44.270;39.487;610;
2.1) Land and buildings;20.257;10.150;2.712;7.373;23;
2.2) Equipment and instruments;144.096;72.538;40.235;30.775;549;
2.3) Acquisition of specific R+D software;8.151;5.713;1.102;1.303;33;
2.4) Otros productos de propiedad intelectual específicos para I+D;10.278;10.015;222;36;5;
1.1) By origin of the funds: Own funds;891.115;711.037;88.338;88.167;3.574;
1.2) By origin of the funds: From companies;247.985;121.595;97.993;25.096;3.301;
1.3) By origin of the funds: Public Administration funds;882.530;107.422;430.689;342.018;2.402;
1.4) By origin of the funds: From Universities;3.851;192;1.388;2.220;50;
1.5) By origin of the funds: From non profit private institutions;47.810;10.756;26.599;7.719;2.737;
1.6) By origin of the funds: Foreign funds;195.959;86.884;71.871;35.483;1.720;
Purchase of services R & D in Biotechnology to (thousands of euros);174.817;145.440;23.461;3.058;2.858;
Purchase of services R & D in Biotechnology to (thousands of euros): in Spain;123.416;95.870;21.807;3.035;2.704;
Purchase of services R & D in Biotechnology to (thousands of euros): Abroad;51.401;49.570;1.654;23;154;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;42,5;39,8;63,3;57,6;61,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;11,9;12,5;6,7;9,1;15,4;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;21,5;18,5;45;40,9;23,1;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;13,3;11,2;26,7;33,3;7,7;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;17,8;15,6;30;42,4;15,4;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and marketing channels;18,5;16,5;27,5;39,4;30,8;
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;15,6;16,1;10;12,1;30,8;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;40,1;40;40;37,9;61,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;54,4;53,9;58,3;57,6;61,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;21,5;21,5;24,2;18,2;23,1;
Notas:
'..'=data not available 

 '.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent 

 (*) Total calculated from the total number of companies with related activities  with Biotechnology and the total Companies from other sectors with activities  in R&D in Biotechnology
Fuente: National Statistics Institute